LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Novavax Inc

Novavax Inc

Closed

SectorHealthcare

9.6 -1.34

Buy Sell

Overview

Share price change

24h

Current

Min

9.42

Max

9.6

Key metrics
By Trading Economics
Income	220M 18M
Sales	77M 147M
P/E Sector Avg	3.907 57.833
EPS	0.11
Profit margin	11.912
Employees	749
EBITDA	220M 29M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+31.7% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	121M 1.6B
Previous open	10.94
Previous close	9.6

News Sentiment

By Acuity

34%

66%

90 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

5.692 / 6.039 Support & Resistance

Novavax Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 17:06 UTC

Major Market Movers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

19 maj 2025, 14:30 UTC

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

31.7% upside

12 Months Forecast

Average 12.67 USD 31.7%

High 19 USD

Low 7 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Novavax Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.692 / 6.039Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

90 / 350 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.